Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

KARACHI: The prices of different makes and models of cars prevailing in Karachi in the week ended Sunday (March ...

It's no fishy proposition — adding the best fish oil or other omega-3 rich supplement to your diet could help protect your ...

Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...

New Delhi: Hetero Healthcare has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

McGrath RentCorp (NASDAQ:MGRC – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday. A number of other ...

Their effect on cancer is associated with alpha-linolenic acid (ALA ... Chia seeds contain 115 mg of potassium and 244 mg of ...